Shanghai Kai Kai Industry Co Ltd B (900943) - Total Liabilities

Latest as of June 2025: $878.36 Million USD

Based on the latest financial reports, Shanghai Kai Kai Industry Co Ltd B (900943) has total liabilities worth $878.36 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shanghai Kai Kai Industry Co Ltd B cash flow conversion to assess how effectively this company generates cash.

Shanghai Kai Kai Industry Co Ltd B - Total Liabilities Trend (2015–2024)

This chart illustrates how Shanghai Kai Kai Industry Co Ltd B's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Shanghai Kai Kai Industry Co Ltd B to evaluate the company's liquid asset resilience ratio.

Shanghai Kai Kai Industry Co Ltd B Competitors by Total Liabilities

The table below lists competitors of Shanghai Kai Kai Industry Co Ltd B ranked by their total liabilities.

Company Country Total Liabilities
Baird Medical Investment Holdings Limited
NASDAQ:BDMD
USA $41.37 Million
KC Feed Co. Ltd
KQ:025880
Korea ₩41.16 Billion
Samchuly Bicycle Co. Ltd
KQ:024950
Korea ₩141.49 Billion
Singbao International Co Ltd
TWO:6130
Taiwan NT$231.12 Million
Sekuro Plastik Ambalaj Sanayi AS
IS:SEKUR
Turkey TL1.19 Billion
Fantasia Holdings Group Co. Limited
F:FT7
Germany €86.26 Billion
LGL Group Inc
NYSE MKT:LGL
USA $1.38 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Shanghai Kai Kai Industry Co Ltd B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Kai Kai Industry Co Ltd B (900943) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.37 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.57 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shanghai Kai Kai Industry Co Ltd B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shanghai Kai Kai Industry Co Ltd B (2015–2024)

The table below shows the annual total liabilities of Shanghai Kai Kai Industry Co Ltd B from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 $835.87 Million +16.17%
2023-12-31 $719.52 Million +14.39%
2022-12-31 $629.00 Million +21.80%
2021-12-31 $516.43 Million -1.19%
2020-12-31 $522.67 Million +0.42%
2019-12-31 $520.47 Million +0.82%
2018-12-31 $516.24 Million -4.35%
2017-12-31 $539.69 Million +1.61%
2016-12-31 $531.13 Million +3.45%
2015-12-31 $513.44 Million --

About Shanghai Kai Kai Industry Co Ltd B

SHG:900943 China Apparel Manufacturing
Market Cap
$33.76 Million
Market Cap Rank
#23311 Global
#4727 in China
Share Price
$0.42
Change (1 day)
+0.96%
52-Week Range
$0.41 - $0.54
All Time High
$1.48
About

Shanghai Kai Kai Industry Company Limited engages in the wholesale and retail of pharmaceutical products in China. The company engages in the wholesale and retail of traditional Chinese and Western medicines; medical devices; reagents; consumables and diagnosis; and treatment services, etc. under the Shang Lei brand, as well as production and sale of Chinese patent medicine under the Jing and Que… Read more